BIRC5 and cancer: Thus, to gain a better understanding of the mechanisms by which oncogenic forms of KRAS drive cancer progression, with the hope that this might highlight new therapeutic strategies for PDAC, we treated MIA PaCa-2 PDAC cells with Sotorasib and found that the normally high expression level of Survivin in these cells was strongly downregulated.